Vaccine makers are depending on the U.S. market as many countries have more limited yearly campaigns for giving updated shots.
For BioNTech, Moderna, and Novavax (NVAX.O), COVID vaccines remain their only approved products.
Shares of Pfizer were up nearly 5%, however, buoyed by a $3.5 billion cost-cutting plan the drugmaker announced late on Friday alongside its new COVID sales outlook.
Moderna, in a statement on Monday, maintained its current revenue forecast of $6 billion to $8 billion for its COVID vaccine for 2023.
Jefferies analyst Michael Yee said Pfizer's new COVID outlook implies lower vaccine sales for Moderna than it had forecast.
Persons:
Dado, BioNTech, Albert Bourla, Bourla, Mani Foroohar, Foroohar, Jefferies, Michael Yee, Ludwig Burger, Rachel More, Michael Erman, Bhanvi Satija, Manas, Jonathan Oatis, Caroline Humer, Bill Berkrot
Organizations:
COVID, Institute for Health, Food, REUTERS, Pfizer, Moderna, Manas Mishra, Thomson
Locations:
Zenica, Bosnia, Herzegovina, Frankfurt, Novavax, U.S, New York, Bengaluru